Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 8 (August)

1. Expression of cellular prion protein in the frontal and occipital lobe in Alzheimer's disease, diffuse Lewy body disease, and in normal brain: an immunohistochemical study.
   J Histochem Cytochem, 53(8): 929-40. [Abstract] [Full-text]
2. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.
   Biochim Biophys Acta, 1751(1): 60-7. [Abstract] [Full-text]
3. Association of interleukin-I beta and receptor antagonist gene polymorphisms with late onset Alzheimer's disease in Taiwan Chinese.
   Eur J Neurol, 12(8): 609-13. [Abstract] [Full-text]
4. The transmethylation cycle in the brain of Alzheimer patients.
   Neurosci Lett, 386(2): 69-71. [Abstract] [Full-text]
5. Immunohistochemical study of the hnRNP A2 and B1 in the hippocampal formations of brains with Alzheimer's disease.
   Neurosci Lett, 386(2): 111-5. [Abstract] [Full-text]
6. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
   Life Sci, 77(15): 1836-43. [Abstract] [Full-text]
7. Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid.
   Neuropeptides, 39(4): 419-26. [Abstract] [Full-text]
8. Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism.
   Cell Mol Neurobiol, 25(3): 475-83. [Abstract] [Full-text]
9. Cyclical mitochondrial deltapsiM fluctuations linked to electron transport, F0F1 ATP-synthase and mitochondrial Na+/Ca+2 exchange are reduced in Alzheimer's disease cybrids.
   Mitochondrion, 5(2): 109-19. [Abstract] [Full-text]
10. A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease.
    Ann Neurol, 58(2): 277-89. [Abstract] [Full-text]
11. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease.
    Hum Mol Genet, 14(16): 2399-404. [Abstract] [Full-text]
12. Multiple ligand binding sites on A beta(1-40) fibrils.
    Amyloid, 12(1): 5-14. [Abstract] [Full-text]
13. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease.
    Am J Epidemiol, 162(4): 305-17. [Abstract] [Full-text]
14. Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy.
    Mov Disord, 20(8): 1031-3. [Abstract] [Full-text]
15. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
    BMJ, 331(7512): 321-7. [Abstract] [Full-text]
16. Telling about the stolen mind.
    Neurol Sci, 26(3): 185-7. [Abstract] [Full-text]
17. Temporal gradients for media-mediated memory: Italian norms.
    Neurol Sci, 26(3): 161-7. [Abstract] [Full-text]
18. Genetic association of alpha2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians.
    Neurosci Lett, 386(3): 176-8. [Abstract] [Full-text]
19. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production.
    J Biol Chem, 280(32): 28912-6. [Abstract] [Full-text]
20. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.
    Arch Intern Med, 165(15): 1737-42. [Abstract] [Full-text]
21. Discomfort in nursing home patients with severe dementia in whom artificial nutrition and hydration is forgone.
    Arch Intern Med, 165(15): 1729-35. [Abstract] [Full-text]
22. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques.
    Biochemistry, 44(32): 10810-21. [Abstract] [Full-text]
23. Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity.
    J Neurochem, 94(4): 1140-5. [Abstract] [Full-text]
24. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain.
    FEBS J, 272(16): 4211-20. [Abstract] [Full-text]
25. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese.
    Neurosci Lett, 387(1): 11-6. [Abstract] [Full-text]
26. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease.
    Eur J Neurosci, 22(3): 617-26. [Abstract] [Full-text]
27. Antipsychotic dose-sparing effect with addition of memantine.
    Ann Pharmacother, 39(9): 1573-6. [Abstract] [Full-text]
28. Alzheimer disease subjects with psychosis have increased schizotypal symptoms before dementia onset.
    Biol Psychiatry, 58(4): 325-30. [Abstract] [Full-text]
29. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy.
    Proc Natl Acad Sci U S A, 102(33): 11906-10. [Abstract] [Full-text]
30. Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy?
    J Neurol Neurosurg Psychiatry, 76(9): 1286-8. [Abstract] [Full-text]
31. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people.
    J Neurol Neurosurg Psychiatry, 76(9): 1194-9. [Abstract] [Full-text]
32. Preclinical Alzheimer's disease: diagnosis and prediction of progression.
    Lancet Neurol, 4(9): 576-9. [Abstract] [Full-text]
33. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort.
    J Am Geriatr Soc, 53(7): 1101-7. [Abstract] [Full-text]
34. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort.
    Dement Geriatr Cogn Disord, 20(2): 198-208. [Abstract] [Full-text]
35. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
    Dement Geriatr Cogn Disord, 20(2): 192-7. [Abstract] [Full-text]
36. Implicit and explicit memory for spatial information in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 20(2): 184-91. [Abstract] [Full-text]
37. A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease.
    Dement Geriatr Cogn Disord, 20(2): 178-83. [Abstract] [Full-text]
38. Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: a combination of techniques that may contribute to the diagnosis of Alzheimer's disease.
    Dement Geriatr Cogn Disord, 20(2): 169-77. [Abstract] [Full-text]
39. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
    Dement Geriatr Cogn Disord, 20(2): 153-7. [Abstract] [Full-text]
40. Evidence of biochemical and biomagnetic interactions in Alzheimer's disease: an MEG and MR spectroscopy study.
    Dement Geriatr Cogn Disord, 20(2): 145-52. [Abstract] [Full-text]
41. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Dement Geriatr Cogn Disord, 20(2): 120-32. [Abstract] [Full-text]
42. Functional disabilities profile of chinese elderly people with Alzheimer's disease - a validation study on the chinese version of the disability assessment for dementia.
    Dement Geriatr Cogn Disord, 20(2): 112-9. [Abstract] [Full-text]
43. No genetic association between ATP binding cassette proteins and Japanese sporadic Alzheimer's disease.
    Dement Geriatr Cogn Disord, 20(2): 95-8. [Abstract] [Full-text]
44. The Alzheimer variant of lewy body disease: a pathologically confirmed case-control study.
    Dement Geriatr Cogn Disord, 20(2): 89-94. [Abstract] [Full-text]
45. In vivo evidence of CHIP up-regulation attenuating tau aggregation.
    J Neurochem, 94(5): 1254-63. [Abstract] [Full-text]
46. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
    J Neurochem, 94(5): 1189-201. [Abstract] [Full-text]
47. Association between acyl-coenzyme A: cholesterol acyltransferase gene and risk for Alzheimer's disease in Chinese.
    Neurosci Lett, 388(1): 17-20. [Abstract] [Full-text]
48. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients.
    Neurosci Lett, 388(1): 49-53. [Abstract] [Full-text]
49. Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women.
    Eur J Hum Genet, 13(9): 1000-6. [Abstract] [Full-text]
50. Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
    Clin Chem, 51(9): 1650-60. [Abstract] [Full-text]
51. Sleep and cognition in people with Alzheimer's disease.
    Issues Ment Health Nurs, 26(7): 687-98. [Abstract] [Full-text]
52. Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid.
    FEBS Lett, 579(21): 4775-80. [Abstract] [Full-text]
53. Implicit memory and Alzheimer's disease neuropathology.
    Brain, 128: 2006-15. [Abstract] [Full-text]
54. Early changes in behavior deficits, amyloid beta-42 deposits and MAPK activation in doubly transgenic mice co-expressing NSE-controlled human mutant PS2 and APPsw.
    Cell Mol Neurobiol, 25(5): 881-98. [Abstract] [Full-text]
55. NSE-controlled carboxyl-terminus of APP gene over-expressing in transgenic mice induces altered expressions in behavior, Abeta-42, and GSK3beta binding proteins.
    Cell Mol Neurobiol, 25(5): 833-50. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.